Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

BMC Pulmonary Medicine

Volumn 1, Issue , 2001, Pages

  Brindle, Richard ^a   Odhiambo, Joseph ^b   Mitchison, Denis ^c  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFATER; STREPTOMYCIN; THIOACETAZONE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; SEROLOGY; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0001837393     PISSN: 14712466     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2466-1-2     Document Type: Article

References (26)

1. Tuberculosis Scientific Blueprint for TB Drug Development. Tuberculosis 2001, 81 (Suppl.1):1-52
2. Mitchison DA: Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993, 147:1062-1063
3. Mitchison DA: Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. J Appl Bacteriol 1996, 81:72S-80S
4. Wallis RS, Perkins MD, Phillips M, Joloba M, Namale A, Johnson JL, Whalen CC, Teixeira L, Demchuk B, Dietze R, et al: Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000, 161:1076-1080
5. Epstein MD, Schluger NW, Davidow AL, Bond SB, Rom WN, Hanna B: Time to detection of M. tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1997, 113:379-386
6. Jindani A, Aber VR, Edwards EA, Mitchison DA: The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:939-949
7. Mitchison DA, Sturm WA: The measurement of early bactericidal activity. In: Bailliere's Clinical Infectious Diseases: Mycobacterial Diseases Part II. (Edited by Malin A, McAdam KPWJ) London, Bailliere Tindall 1997 185-206
8. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Lam KM, Lam CW, Sole KM, Mitchison DA, and the EBA Collaborative Study Group: A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000, 45:859-870
9. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P: Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993, 147:958-961
10. East African/British Medical Research Council: Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet 1974, 2:237-240
11. Sirgel F, Venter A, Mitchison D: Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother 2001, 47:177-182
12. Dickinson JM, Mitchison DA: Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981, 123:367-371
13. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, Coates ARM: Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampicin or pyrazinamide. J Bacteriol 2000, 182:6358-6365
14. McCune RM, Tompsett R, McDermott W: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J Exp Med 1956, 104:763-803
15. Botha FJH, Sirgel FA, Parkin DP, van de Wal BW, Donald PR, Mitchison DA: Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996, 86:155-158
16. Mitchison DA: The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985, 66:219-225
17. East and Central African/British Medical Research Council (fifth Collaborative Study): Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Final report. Tubercle 1986, 67:5-15
18. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, 3 × weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Am Rev Respir Dis 1991, 143:700-706
19. Mitchison DA: The Garrod Lecture. Understanding the chemotherapy of tuberculosis-current problems. J Antimicrob Chemother 1992, 29:477-493
20. Canetti G: The tubercle bacillus in the pulmonary lesion of man: histobacteriology and its bearing on the therapy of pulmonary tuberculosis. New York, Springer 1955
21. Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6 month) mortality. Am Rev Respir Dis 1992, 146:849-854
22. Mitchison DA, Allen BW, Carrol L, Dickinson JM, Aber VR: A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1972, 5:165-175
23. Royston P: A toolkit for testing for non-normality in complete and censored samples. Statistician 1993, 42:37-43
24. Box GEP, Cox DR: An analysis of transformations. J R Stat Soc 1964, 26:211-243
25. Tukey JW: Exploratory Data Analysis. Reading, MA. Addison-Wesley Publishing Company 1977
26. McCune RM, Tompsett R, McDermott W: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956, 104:763-803